Recombinant Human IL-5 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-01909P-100UG
Human IL-5 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human IL-5 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-01909P-100UG
Collections: Other recombinant proteins, Recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human IL-5 Protein is expressed from HEK293 with His tag and Avi tag at the N-Terminus.It contains Ile20-Ser134. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | P05113 |
Target Symbol | IL-5 |
Synonyms | Interleukin-5; IL-5; T-cell replacing factor; TRF; EDF |
Species | Human |
Expression System | HEK293 |
Tag | N-His-Avi |
Expression Range | Ile20-Ser134 |
Mol. Weight | The protein has a predicted MW of 16.1 kDa. Due to glycosylation, the protein migrates to 18-25 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Human IL-5, His Tag at 0.5ug/ml (100ul/Well) on the plate. Dose response curve for Human IL-5 R alpha, hFc Tag with the EC50 of 6.9ng/ml determined by ELISA (QC Test). The affinity constant of 4.9nM as determined in SPR assay (Biacore T200). Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | IL-5 is an important cytokine for priming and survival of mature eosinophils and for proliferation and maturation of their progenitors. IL-5(Rα) targeting will be increasingly used in diseases where eosinophils are the key immune effector cells such as eosinophilic asthma (EA), hypereosinophilic syndrome (HES), eosinophilic esophagitis (EE), and eosinophilic granulomatosis with polyangiitis (EGPA). |